



**REMARKS**

Claim 1 has been amended to incorporate the recitations of claims 4 and 7 therein, and claims 2-4 and 7 have been canceled accordingly. Claim 5 has been amended for purposes of further clarification without changing its scope.

Entry of the above amendment is respectfully requested.

**Anticipation Rejection over Lin et al.**

On page 2 of the Office Action, claims 1-3 and 5-7 are rejected under 35 U.S.C. 102(e) as being anticipated by Lin et al., U.S. Patent 6,340,734.

In response to this rejection, claim 1 has been amended to incorporate the recitations of claim 4, which was not included in this rejection. In this regard, Applicants submit that Lin et al. does not disclose a hydroxybenzylsilsesquioxane unit, which has been introduced into amended claim 1 from original claim 4.

Thus, Applicants submit that the invention as recited in the amended claims is not anticipated by Lin et al., and withdrawal of this rejection is respectfully requested.

**Anticipation Rejection over Tokutake et al.**

On page 2 of the Office Action, claims 1-6 are rejected under 35 U.S.C. 102(b) as being anticipated by Tokutake et al., JP 4-130324.

In response to this rejection, claim 1 has been amended to incorporate the recitations of claim 7, which was not included in this rejection. In this regard, Applicants submit that JP-A-4-130324 does not disclose a weight average molecular weight of 1,000-100,000, which has been introduced into amended claim 1 from original claim 7.

Thus, Applicants submit that the invention as recited in the amended claims is not anticipated by JP-A-4-130324, and withdrawal of this rejection is respectfully requested.

### Double Patenting Rejection

On page 3 of the Office Action, claims 1-5 are rejected under the judicially created doctrine of double patenting over claims 1-4 of U.S. Patent No. 6,787,284.


In response, Applicants submit herewith a terminal disclaimer to obviate this rejection. Accordingly, withdrawal of this rejection is respectfully requested.

### Conclusion

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Bruce E. Kramer  
Registration No. 33,725

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: August 25, 2005